A Phase 1a Open-Label Study to Assess the Safety and Pharmacokinetics of a Single ZMapp Administration in Healthy Adult Volunteers
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Porgaviximab (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions; Pharmacokinetics
- 28 Dec 2017 Planned End Date changed from 31 Jan 2025 to 27 Dec 2017.
- 28 Dec 2017 Planned primary completion date changed from 31 Jan 2025 to 27 Dec 2017.
- 28 Dec 2017 Status changed from recruiting to withdrawn prior to enrolment.